Patient-specific major histocompatibility complex class I molecules presenting tumor neoantigen peptides (HLA-I/Neoantigen complex)

Patient-specific MHC class I molecules presenting tumor neoantigen peptides are specialized protein complexes that play a central role in the immune system's ability to distinguish malignant cells from healthy tissue. These complexes consist of a polymorphic Human Leukocyte Antigen (HLA) class I molecule, a beta-2 microglobulin subunit, and a short peptide (typically 8-11 amino acids) derived from a somatic mutation unique to the patient's tumor (Source: NIH National Cancer Institute). Because these neoantigens are not present in the normal genome, they are recognized as foreign by the adaptive immune system, specifically by CD8+ cytotoxic T cells (Source: Frontiers in Immunology, 2021, PMID: 34122451). Therapeutic strategies targeting these complexes include personalized cancer vaccines, such as mRNA or peptide-based platforms, which aim to prime and expand the patient's endogenous T-cell repertoire against these specific markers (Source: Journal of Hematology & Oncology, 2023, PMID: 37143123). Additionally, adoptive cell therapies like TCR-T use engineered T cells to directly target a specific neoepitope-HLA combination. The clinical success of these therapies is highly dependent on the accurate identification of mutations through genomic sequencing and the prediction of which peptides will successfully bind to the patient's specific HLA alleles (Source: Nature, 2017, PMID: 28700575).

Other names

Neoepitope-HLA-I complexTumor-specific antigen (TSA) complexMHC-I/Neoantigen complexPersonalized neoantigen-MHC complexMutated peptide-HLA complex

Recognition of the peptide-MHC complex by the T-cell receptor (TCR) of CD8+ cytotoxic T lymphocytes, leading to the activation of the immune response and subsequent lysis of the tumor cell (Source: Nature Reviews Cancer, 2017, PMID: 28233802).